Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04752566
Recruitment Status : Completed
First Posted : February 12, 2021
Last Update Posted : August 29, 2022
Information provided by (Responsible Party):

Brief Summary:

This is a Phase 3, prospective, multicenter, placebo controlled, double blind, randomized study to investigate the efficacy and safety of eculizumab in participants with severe GBS, defined using the Hughes Functional Grade (FG) scale as progressively deteriorating FG3 or FG4/FG5 within 2 weeks from onset of weakness due to GBS.

This study will be conducted only at sites in Japan.

Condition or disease Intervention/treatment Phase
Guillain-Barre Syndrome Biological: Eculizumab Drug: Placebo Phase 3

Detailed Description:
Eligible participants will be randomized to receive intravenous (IV) infusion of eculizumab or placebo at a 2:1 ratio. All participants will be on concomitant IV immunoglobulin G (Ig) therapy as per standard of care.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)
Actual Study Start Date : March 8, 2021
Actual Primary Completion Date : August 3, 2022
Actual Study Completion Date : August 3, 2022

Arm Intervention/treatment
Experimental: Eculizumab
Participants will receive eculizumab.
Biological: Eculizumab
Eculizumab will be administered via IV infusion once a week for 4 weeks.
Other Name: Soliris

Placebo Comparator: Placebo
Participants will receive placebo.
Drug: Placebo
Placebo will be administered via IV infusion once a week for 4 weeks.

Primary Outcome Measures :
  1. Time To First Reaching A Hughes FG Score ≤ 1 [ Time Frame: Up to Week 24 ]

Secondary Outcome Measures :
  1. Proportion Of Participants With A Hughes FG Score ≤ 1 [ Time Frame: Week 24 ]
  2. Proportion Of Participants With A Hughes FG Score Improvement Of ≥ 3 [ Time Frame: Week 24 ]
  3. Proportion Of Participants With A Hughes FG Score ≤ 1 [ Time Frame: Week 8 ]
  4. Incidence Of Treatment-emergent Adverse Events [ Time Frame: Up to Week 24 ]
  5. Free Complement Component 5 In Serum [ Time Frame: Week 24 ]
  6. Hemolytic Complement Activity In Serum [ Time Frame: Week 24 ]
  7. Length Of Stay In The Hospital [ Time Frame: Up to Week 24 ]
  8. Duration Of Ventilator Support [ Time Frame: Up to Week 24 ]
  9. Concentration Of Eculizumab In Serum [ Time Frame: Up to Week 24 ]
  10. Incidence Of Antidrug Antibodies [ Time Frame: Up to Week 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants who meet the GBS criteria.
  • Participants who were able to run prior to onset of GBS symptoms.
  • Participants with onset of weakness due to GBS < 2 weeks before screening.
  • Participants unable to walk unaided for ≥ 5 meters (progressively deteriorating FG3 or FG4 to FG5).
  • Participants who are already on IVIg or deemed eligible for and who will start IVIg.
  • Participants who can start their first dose of study drug before the end of the IVIg treatment period.

Exclusion Criteria:

  • Participants who have previously received or are currently receiving treatment with complement modulators.
  • Participants who have been administered another investigational product within 30 days or 5 half-lives (whichever is longer) prior to providing consent or are currently participating in another interventional study.
  • Participants who have received rituximab within 12 weeks prior to screening.
  • Participants who are being considered for or are already on plasmapheresis.
  • Participants who have received immunosuppressive treatment during the 4 weeks prior to providing consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04752566

Layout table for location information
Clinical Trial Site
Bunkyo-ku, Japan, 113-8519
Clinical Trial Site
Chiba, Japan, 260-8677
Clinical Trial Site
Fuchu, Japan, 183-0042
Clinical Trial Site
Fukuoka, Japan, 814-0180
Clinical Trial Site
Gifu, Japan, 501-1194
Clinical Trial Site
Hiroshima, Japan, 730-8518
Clinical Trial Site
Kagoshima, Japan, 890-8520
Clinical Trial Site
Kawagoe, Japan, 350-8550
Clinical Trial Site
Kawasaki, Japan, 216-8511
Clinical Trial Site
Kitakyushu, Japan, 807-8556
Clinical Trial Site
Kobe, Japan, 650-0047
Clinical Trial Site
Kumamoto, Japan, 860-8556
Clinical Trial Site
Kurashiki, Japan, 710-8602
Clinical Trial Site
Kyoto, Japan, 602-8566
Clinical Trial Site
Matsumoto, Japan, 390-8621
Clinical Trial Site
Mibu, Japan, 321-0293
Clinical Trial Site
Mitaka, Japan, 181-8611
Clinical Trial Site
Nagoya, Japan, 466-8560
Clinical Trial Site
Niigata, Japan, 951-8520
Clinical Trial Site
Nishinomiya, Japan, 663-8501
Clinical Trial Site
Osakasayama, Japan, 589-8511
Clinical Trial Site
Sagamihara, Japan, 252-0375
Clinical Trial Site
Sapporo, Japan, 060-8648
Clinical Trial Site
Sendai, Japan, 983-8520
Clinical Trial Site
Ube, Japan, 755-8505
Clinical Trial Site
Yokohama, Japan, 236-0004
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Alexion Identifier: NCT04752566    
Other Study ID Numbers: ECU-GBS-301
First Posted: February 12, 2021    Key Record Dates
Last Update Posted: August 29, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alexion:
C5 Inhibition Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Guillain-Barre Syndrome
Pathologic Processes
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases
Post-Infectious Disorders
Chronic Disease
Disease Attributes
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs